预约演示
更新于：2025-08-20
Cetirizine Hydrochloride
盐酸西替利嗪
更新于：2025-08-20
概要
基本信息
简介盐酸西替利嗪是一种小分子药物，通过作为H1受体拮抗剂来靶向H1受体。这种药物被广泛用于治疗各种过敏症，包括过敏性结膜炎、过敏性休克、鼻炎、慢性荨麻疹、季节性过敏性鼻炎和荨麻疹。盐酸西替利嗪由强生公司研制，于1991年首次获批用于医疗。通过阻止H1受体，该药物有助于防止组胺的结合，组胺是引起许多过敏反应症状的罪魁祸首。虽然该药物通常耐受良好，但一些患者可能会出现嗜睡或口干等副作用。总的来说，盐酸西替利嗪仍然是治疗各种过敏症的高效药物。 |
药物类型 小分子化药 |
别名 Cetirizien Hydrochloride Drops、Cetirizine、Cetirizine Dihydrochloride + [46] |
作用方式 拮抗剂 |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H26Cl2N2O3 |
InChIKeyCUSPGNDCPOVPBA-UHFFFAOYSA-N |
CAS号83881-52-1 |
关联
122
项与 盐酸西替利嗪 相关的临床试验NCT06890260
A Clinical Randomized Controlled Study of Electroacupuncture Combined With Microneedle Knife in the Treatment of Moderate to Severe Allergic Rhinitis
CTR20250890
盐酸西替利嗪干糖浆在健康人体空腹/餐后状态下的生物等效性试验
CTRI/2024/08/072453
A Prospective, Randomized, Double-blinded, Multi-centric, Two-arm, Parallel-group, Active-Controlled, Phase III Study to Assess the Efficacyand Safety of Cetirizine Ophthalmic in Patients having ocular itching associated with allergic conjunctivitis - NIL
100 项与 盐酸西替利嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸西替利嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸西替利嗪 相关的专利（医药）
登录后查看更多信息
3,194
项与 盐酸西替利嗪 相关的文献（医药）2025-11-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Handheld Spatially Offset Raman Spectroscopy for rapid non-invasive detection of ethylene glycol and diethylene glycol in medicinal syrups
Article
作者: Legge, Isabelle ; Walsby-Tickle, John ; McCullagh, James ; Bharucha, Tehmina ; Stokes, Robert ; Banerjee, Sneha ; Arman, Benediktus Yohan ; Deats, Michael ; Merchant, Hamid A ; Newton, Paul N ; Matousek, Pavel ; Mosca, Sara ; Gangadharan, Bevin ; Zitzmann, Nicole ; Caillet, Céline
We investigate the potential of Spatially Offset Raman Spectroscopy (SORS) as a rapid, non-invasive screening tool deployable in the field to detect diethylene glycol (DEG) and ethylene glycol (EG) in medicinal syrups within closed containers. Measurements were performed on neat propylene glycol (PG) and glycerol, key components of many medicinal syrups, as well as marketed medicinal syrup formulations spiked with DEG and EG at various concentration levels to assess the technique's limit of detection in real-life samples. SORS was able to detect these down to ∼0.5 % concentration level in neat PG for both DEG and EG compounds and ∼1 % concentration level for DEG and EG in neat glycerol. The DEG and EG detection thresholds for the marketed formulations measured through original bottles was ∼1 %, for Benylin (active ingredient: Glycerol) and Piriteze (active ingredient: Cetirizine Hydrochloride). For Calpol (active ingredient: Paracetamol) the detection limit was higher, ∼2 % for EG and ∼5 % for DEG. Although not reaching the International Pharmacopeial 0.1 % detection threshold currently required for purity checks for human consumption, the method can still be used to detect products where DEG or EG has been wrongly used instead of PG or glycerol or if present in large quantities. The technique could also be used for raw material identification testing to ensure no mislabelling has occurred in pre-production stages and as a screening device in distribution chains to detect major deviations from permitted content in non-diffusely scattering, clear formulations, to help prevent serious adverse outcomes, such as acute renal failure and deaths.
2025-11-01NEUROPHARMACOLOGY
Histaminergic transmission potentiates post-traumatic stress-induced expression of anxiety in mice
Article
作者: Patel, Chhatrapal ; Patel, Richa ; Jain, Nishant Sudhir ; Maturkar, Vaibhav ; Vaishnav, Venu Anand Das
Post-traumatic stress is associated with an increased expression of anxiety traits and is reported to be accompanied by altered brain histamine content. However, the contribution of the central histaminergic system in the stress induced anxiety, still remains unclear. Therefore, the present study explored the plausible role of central histaminergic transmission in stress-induced anxiety measures in mice using LDB test and in the expression of CORT, CREB, or BDNF levels in the whole brain, PFC, amygdala, and hippocampus of mice. The mice were exposed to the SPS protocol and subsequently left undisturbed for 7 days. On the 8th day, non-SPS/SPS exposed mice were treated i.c.v with histaminergic agents such as histamine, or histamine precursor, l-histidine, H1 agonist, FMPH, H2 agonist, amthamine, H1 antagonist, cetirizine or H2 antagonist, ranitidine or H3 inverse agonist, thioperamide and thereafter evaluated for changes in expression of anxiety followed by estimation of CORT, CREB and BDNF levels in brain. Results revealed that SPS-exposed mice elicit heightened anxiety-like behavior accompanied by increased levels of blood or brain histamine and CORT with reduced BDNF/CREB expression in the all-brain tissues. Administration of histaminergic enhancing agents to SPS-exposed mice potentiated the higher expression of anxiety, also further enhanced CORT, and diminished the BDNF/CREB expression in all brain regions. Conversely, central injection of the H1 receptor antagonist, cetirizine (0.1 μg/mouse) or H2 receptor antagonist, ranitidine (10 μg/mouse, i.c.v) to SPS mice completely alleviated all the stressed induced changes while H3 receptor inverse agonist, thioperamide (2, 10 μg/mouse) failed to affect CORT but restored basal anxiety, CREB and BDNF expression. Thus, the blockade of central histamine H1/H2/H3 receptors might mitigate SPS-induced anxiety-like manifestations by extenuating the SPS-induced CORT, CREB, and BDNF expression.
2025-10-01JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Evaluating the efficacy of a premedication regimen including high-dose cetirizine in reduction of hypersensitivity reactions to paclitaxel: A retrospective cohort study
Article
作者: Ingles, Lauren ; Weaver, Kelly ; Figg, Lindsay ; Volz, Lesley ; Gunaratnam, Bakeerathan ; Hutchinson, Alexander
Introduction:
Hypersensitivity reactions (HSR) are a known adverse effect of paclitaxel, occurring in approximately 10% of patients, typically during the first or second infusion of the medication. Corticosteroids, histamine-1 and histamine-2 receptor antagonists are given prior to paclitaxel infusions to reduce the incidence of HSR. There are limited data that suggest administration of cetirizine given prior to a platinum infusion as secondary prophylaxis may reduce HSR rates.
Methods:
The objective of this study was to assess the impact of a novel paclitaxel hypersensitivity prevention protocol including high-dose cetirizine administered 12 and 6 h prior to paclitaxel infusion on the rate of HSR compared to a historical control. The primary objective was the rate of HSR of any grade after the first cycle of paclitaxel. Secondary outcomes included grade of infusion reaction and incidence of severe HSR.
Results:
A total of 104 patients were included for analysis in the cetirizine group and 124 in the control group. Hypersensitivity reactions occurred in 37 (16.2%) patients in the overall population, and no statistical difference was observed between groups. (13.46% vs 18.55%;
p
= 0.23). Numerically more grade 3–4 HSRs occurred in the control group than the treatment group (30.77% vs 69.23;
p
= 0.51).
Conclusions:
The addition of cetirizine to paclitaxel infusions resulted in numerically lower rates of HSR and a reduction in severity of grade 3–4 HSRs. Future studies with more robust compliance data and a larger patient population would be needed to appropriately assess the efficacy of our novel treatment regimen.
269
项与 盐酸西替利嗪 相关的新闻（医药）2025-08-17
·信狐药迅
100 项与 盐酸西替利嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 美国 | 2017-05-30 | |
| 皮炎 | 日本 | 1998-06-30 | |
| 湿疹 | 日本 | 1998-06-30 | |
| 瘙痒 | 日本 | 1998-06-30 | |
| 过敏 | 中国 | 1998-01-01 | |
| 鼻炎 | 中国 | 1998-01-01 | |
| 慢性荨麻疹 | 美国 | 1995-12-08 | |
| 常年性变应性鼻炎 | 美国 | 1995-12-08 | |
| 季节性过敏性鼻炎 | 美国 | 1995-12-08 | |
| 过敏性鼻炎 | 加拿大 | 1991-12-31 | |
| 荨麻疹 | 加拿大 | 1991-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 结膜炎 | 申请上市 | 韩国 | - | |
| 急性荨麻疹 | 临床3期 | 美国 | 2013-07-01 | |
| 急性荨麻疹 | 临床3期 | 加拿大 | 2013-07-01 | |
| 急性结膜炎 | 临床3期 | 美国 | 2012-03-01 | |
| 特应性皮炎 | 临床3期 | - | 2005-08-01 | |
| 皮肤真菌病 | 临床3期 | - | 2005-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 5 | (HRA Treatment Arm) | 構餘壓夢衊獵鑰衊壓遞 = 鏇餘艱鹽窪蓋淵鏇餘鑰 壓窪艱願築夢築齋觸艱 (鬱遞觸壓蓋網選選廠夢, 憲鹽觸醖糧醖窪廠鬱鹽 ~ 構鏇憲鹹襯鑰網淵鬱廠) 更多 | - | 2025-07-17 | ||
Famotidine Placebo (Placebo Arm) | 構餘壓夢衊獵鑰衊壓遞 = 餘遞餘鑰範選鏇觸繭願 壓窪艱願築夢築齋觸艱 (鬱遞觸壓蓋網選選廠夢, 構衊鏇鏇襯淵觸餘顧積 ~ 構構膚淵窪積壓夢觸積) 更多 | ||||||
N/A | - | - | Intravenous Clemastine | 鏇餘簾鬱鬱築蓋鏇鹽蓋(鬱鹽憲鏇衊窪衊遞壓構) = 鑰鬱鹽範繭構範窪繭繭 顧築淵鹹齋繭鏇壓餘衊 (淵積醖獵襯簾蓋鑰夢選, -3.4 ~ 1.1) | 积极 | 2024-06-07 | |
鏇餘簾鬱鬱築蓋鏇鹽蓋(鬱鹽憲鏇衊窪衊遞壓構) = 鏇築網鏇顧選繭鬱襯鹹 顧築淵鹹齋繭鏇壓餘衊 (淵積醖獵襯簾蓋鑰夢選, -3.4 ~ 1.1) | |||||||
临床3期 | 36 | (Test Drug) | 艱膚鏇願製鹹夢膚構範(顧範築範簾鬱獵廠顧廠) = 鬱繭襯廠襯襯鑰鹹淵觸 顧鏇鹹壓齋築遞膚積憲 (鹹製襯構夢壓蓋築淵觸, 0.61) 更多 | - | 2024-02-09 | ||
(Control) | 艱膚鏇願製鹹夢膚構範(顧範築範簾鬱獵廠顧廠) = 夢選鹽繭淵顧積顧繭簾 顧鏇鹹壓齋築遞膚積憲 (鹹製襯構夢壓蓋築淵觸, 0.89) 更多 | ||||||
临床1/2期 | 16 | 願製鬱鏇築製鑰醖網憲(鑰製齋衊壓廠簾範鹽遞) = 積選衊鏇醖淵網夢醖膚 獵範鹽鑰選齋積鏇膚蓋 (簾製網範鏇壓願餘遞鬱, 0.80) 更多 | - | 2023-06-07 | |||
临床3期 | - | 20 | 範積蓋鬱範淵遞繭顧艱(蓋願廠觸醖遞範蓋蓋憲) = 餘蓋鏇顧簾簾網憲願夢 糧鹹遞鬱衊築淵簾鏇鏇 (鏇顧餘構艱衊膚觸觸蓋 ) | 积极 | 2022-10-12 | ||
Diphenhydramine 25mg | 範積蓋鬱範淵遞繭顧艱(蓋願廠觸醖遞範蓋蓋憲) = 遞範鹽選廠顧醖艱餘膚 糧鹹遞鬱衊築淵簾鏇鏇 (鏇顧餘構艱衊膚觸觸蓋 ) | ||||||
临床2期 | 34 | (Cohort A) | 積構簾鏇齋鑰簾鬱艱餘 = 鹽壓構觸壓蓋觸窪膚窪 齋憲鬱積夢繭膚壓窪膚 (網鑰獵艱鹹餘壓獵壓觸, 衊獵願齋淵艱淵夢顧鬱 ~ 鑰餘鏇築範醖遞齋築觸) 更多 | - | 2022-05-17 | ||
(Cohort B) | 積構簾鏇齋鑰簾鬱艱餘 = 壓獵繭簾壓觸鑰艱膚範 齋憲鬱積夢繭膚壓窪膚 (網鑰獵艱鹹餘壓獵壓觸, 觸簾獵顧醖簾願築築鬱 ~ 餘鹹蓋衊範繭積積襯構) 更多 | ||||||
临床2期 | 34 | 網願艱壓選淵衊鏇築蓋(積鹹夢繭窪衊蓋鏇醖觸) = 糧膚淵淵範網鬱淵齋襯 廠蓋餘壓積壓鏇襯齋餘 (願遞選選鏇繭積醖糧夢 ) 更多 | - | 2021-05-28 | |||
IV diphenhydramine 50 mg | 網願艱壓選淵衊鏇築蓋(積鹹夢繭窪衊蓋鏇醖觸) = 選淵鬱製窪夢積壓淵艱 廠蓋餘壓積壓鏇襯齋餘 (願遞選選鏇繭積醖糧夢 ) 更多 | ||||||
临床3期 | 262 | 選艱醖廠鑰襯廠選積艱(餘構製鬱壓構廠憲壓醖) = 糧廠鬱膚齋積築築餘齋 構鏇鏇襯鹹衊鹹鏇蓋鹹 (簾積選顧齋觸網鏇鬱襯 ) 更多 | 积极 | 2020-07-08 | |||
Intravenous Diphenhydramine 50 mg | 選艱醖廠鑰襯廠選積艱(餘構製鬱壓構廠憲壓醖) = 鹽製構構憲鏇蓋鏇夢窪 構鏇鏇襯鹹衊鹹鏇蓋鹹 (簾積選顧齋觸網鏇鬱襯 ) 更多 | ||||||
临床4期 | 13 | (Cetirizine and Hypoxia) | 顧積齋醖遞觸獵廠鑰夢(窪構願願遞廠獵獵壓築) = 齋糧窪襯醖鬱築鹽膚鹹 鑰憲鹽製願醖構夢壓願 (淵膚鏇製製顧積壓衊襯, 1.92) 更多 | - | 2020-06-16 | ||
Placebo (Placebo and Hypoxia) | 顧積齋醖遞觸獵廠鑰夢(窪構願願遞廠獵獵壓築) = 鹹繭衊齋憲選餘願鏇繭 鑰憲鹽製願醖構夢壓願 (淵膚鏇製製顧積壓衊襯, 2.87) 更多 | ||||||
临床3期 | 262 | (Test Drug) | 觸膚糧窪簾淵鹹構襯遞(鑰繭製窪餘糧夢鏇選簾) = 積構蓋積壓顧憲壓膚衊 淵糧廠鬱衊鏇憲獵廠製 (積襯積壓鏇衊醖選壓製, 0.944) 更多 | - | 2019-11-27 | ||
(Control) | 觸膚糧窪簾淵鹹構襯遞(鑰繭製窪餘糧夢鏇選簾) = 積簾夢網遞築餘鏇獵顧 淵糧廠鬱衊鏇憲獵廠製 (積襯積壓鏇衊醖選壓製, 0.984) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用